Quoin Pharmaceuticals, Ltd. Q2 FY2022 earnings call

Key Achievements and Updates

• Clinical Progress: Lead asset QRX003 for Netherton Syndrome is in clinical testing under an open IND. Submitted a briefing document to EMA and received constructive scientific advice, enabling coordinated development for US and EU. Established 8 global commercialization partnerships spanning 60 countries. In-licensed two additional rare disease assets.
• Capital Raise: Successfully closed a heavily oversubscribed and twice upsized capital raise, providing sufficient runway into 2024.
• Commercialization Strategy: Intend to self-commercialize in US and Europe with a compact sales force (30-40 people) weighted towards medical affairs. Have established global partnerships covering 60 countries, leveraging advocacy groups and treating physicians for efficient product access.

No detailed financial performance for product segments provided in the transcript.

Forward-Looking Statements

• The capital raise provides cash runway to fund operations into 2024, beyond key inflection points. Plans to continue developing QRX003 and pipeline products, with initial clinical data for additional indications within 12-18 months.

Risks Mentioned

• Forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from forward-looking statements. For more information, see risk factors in the company's SEC filings.

Q: Regarding European development plan, can data from the US be used for European submission?

A: Yes, no additional clinical testing is required. The same program will suffice for approval in the US, EU, Canada, Australia, and other countries.

Q: Trial design and endpoints?

A: There are multiple endpoints, and no primary endpoint is designated yet. The trial has flexibility in determining the primary endpoint based on the best clinical outcome.

Q: Differences between QRX003 and 007?

A: QRX003 is a smaller molecule, while 007 is a biologic. The two assets could potentially be used in combination for a more effective treatment.

Q: Priority review voucher?

A: Will file for pediatric rare disease designation later this year or early next year. Conversations regarding the voucher will start after the product is approved, and companies typically wait until the voucher is secured before entering discussions.